TY - JOUR
T1 - Are metabolic indices different between drug-naïve first-episode psychosis patients and healthy controls?
AU - Sengupta, Sarojini
AU - Parrilla-Escobar, Maria A.
AU - Klink, Ruby
AU - Fathalli, Ferid
AU - Ying Kin Ng, Kin Ng
AU - Stip, Emmanuel
AU - Baptista, Trino
AU - Malla, Ashok
AU - Joober, Ridha
N1 - Funding Information:
Funding for the study was provided by Valorisation de Recherche de Quebec and the Sackler Foundation. M.A. P-E was supported by grants received from the Fundacion Espanola de Psiquiatria y Salud Mental and Alicia Koplowitz Foundation. The senior authors are supported through salary awards from the Canada Research Chair program (A.M.) and Fond de Rechereche de Sante Quebec (R.J.). Each of these funding sources was neither involved in the study design, nor in the collection, analysis and interpretation of data, writing of the report and decision to submit the paper for publication.
PY - 2008/7
Y1 - 2008/7
N2 - Objective: To compare glucose and lipid metabolism parameters between drug-naïve first-episode psychosis (FEP) patients with a diagnosis of schizophrenia spectrum disorder and healthy controls matched for age, ethnicity, and gender. Method: Baseline evaluations of fasting glucose and lipid metabolism parameters and the oral glucose tolerance test were performed with FEP patients (n = 38), having no more than 10 days of cumulative exposure to antipsychotic medication, and normal community controls (n = 36). Analysis of variance (ANOVA) was conducted to examine between group differences. Results: FEP patients did not show a higher prevalence of the precursors to diabetes (impaired fasting glucose, impaired glucose tolerance, insulin resistance), and no significant difference in β-cell function or lipid profile measures, compared to healthy controls. FEP patients showed a higher waist to hip ratio compared to controls. Conclusions: FEP patients having a schizophrenia spectrum disorder do not differ from healthy controls, in their baseline measures of glucose and lipid metabolites, nor in the prevalence of diabetes or its precursors, before (or close to) the onset of antipsychotic treatment.
AB - Objective: To compare glucose and lipid metabolism parameters between drug-naïve first-episode psychosis (FEP) patients with a diagnosis of schizophrenia spectrum disorder and healthy controls matched for age, ethnicity, and gender. Method: Baseline evaluations of fasting glucose and lipid metabolism parameters and the oral glucose tolerance test were performed with FEP patients (n = 38), having no more than 10 days of cumulative exposure to antipsychotic medication, and normal community controls (n = 36). Analysis of variance (ANOVA) was conducted to examine between group differences. Results: FEP patients did not show a higher prevalence of the precursors to diabetes (impaired fasting glucose, impaired glucose tolerance, insulin resistance), and no significant difference in β-cell function or lipid profile measures, compared to healthy controls. FEP patients showed a higher waist to hip ratio compared to controls. Conclusions: FEP patients having a schizophrenia spectrum disorder do not differ from healthy controls, in their baseline measures of glucose and lipid metabolites, nor in the prevalence of diabetes or its precursors, before (or close to) the onset of antipsychotic treatment.
KW - First-episode psychosis
KW - Glucose metabolism
KW - Impaired glucose tolerance
KW - Insulin resistance
KW - Lipid metabolism
KW - Schizophrenia spectrum disorder
UR - http://www.scopus.com/inward/record.url?scp=46249133594&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=46249133594&partnerID=8YFLogxK
U2 - 10.1016/j.schres.2008.02.013
DO - 10.1016/j.schres.2008.02.013
M3 - Article
C2 - 18396386
AN - SCOPUS:46249133594
SN - 0920-9964
VL - 102
SP - 329
EP - 336
JO - Schizophrenia Research
JF - Schizophrenia Research
IS - 1-3
ER -